When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. A study by Yale Cancer Center researchers published today in the Journal of Clinical Oncology (JCO) shows a checkpoint inhibitor immunotherapy ...
Nov 9, 2018
0
85
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...
Sep 25, 2018
0
5
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) ...
Sep 24, 2018
0
1
An Ontario clinical study that shows adding PET imaging to conventional CT imaging to stage locally advanced cervix cancer can change treatment means newly diagnosed women in this province may also receive PET imaging.
Sep 14, 2018
0
1
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has become a popular method for determining the stage of a patient's prostate cancer. However, researchers have identified a major pitfall ...
Sep 7, 2018
0
1
Scientists have arrived at a key understanding about how cancers in individual patients spread, or metastasize, a study from the Stanford University School of Medicine and other collaborating institutions reports.
Sep 6, 2018
0
116
A new study from Uppsala University shows that many patients with colon cancer do not need any chemotherapy and that among patients who benefit from chemotherapy it does not have to be as intense for everyone.
Aug 30, 2018
0
0
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas ...
Aug 22, 2018
0
355
ORLANDO (July 23, 2018): Patients with colorectal cancer tumors on the right side may have poorer five-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study ...
Jul 23, 2018
0
2
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent ...
Jul 10, 2018
0
28
